The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity

Although the recently concluded CLEOPATRA trial showed clinical benefits of combining trastuzumab and pertuzumab for treating HER2-positive metastatic breast cancer, trastuzumab monotherapy is still the mainstay in adjuvant settings. Since trastuzumab resistance occurs in over half of these cancers,...

Descripción completa

Detalles Bibliográficos
Autores principales: Tóth, Gábor, Szöőr, Árpád, Simon, László, Yarden, Yosef, Szöllősi, János, Vereb, György
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2016
Materias:
Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058622/
https://www.ncbi.nlm.nih.gov/pubmed/27380003
http://dx.doi.org/10.1080/19420862.2016.1204503

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5058622/
https://www.ncbi.nlm.nih.gov/pubmed/27380003
http://dx.doi.org/10.1080/19420862.2016.1204503

Ejemplares similares